Financials Connect Biopharma Holdings Limited
Equities
CNTB
US2075231017
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.52 USD | +18.75% |
|
+9.35% | +28.81% |
12/06 | Connect Biopharma Names New Chief Executive, Chair | MT |
12/06 | Connect Biopharma Holdings Limited Announces Board and Management Changes | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,735 | 329.3 | 461.2 | 608.6 | - | - |
Enterprise Value (EV) 2 | 28.46 | -729.2 | -397.6 | -221.5 | -878.5 | -351.3 |
P/E ratio | -1.31 x | -0.41 x | -1.09 x | 0.93 x | -2.07 x | -1.56 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | 0.53 x | 2.38 x | 2.94 x |
EV / Revenue | - | - | - | -0.19 x | -3.43 x | -1.7 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -0.05 x | 1.07 x | - | -0.35 x | 2.76 x | 0.85 x |
FCF Yield | -2,005% | 93.2% | - | -284% | 36.3% | 117% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 53,023 | 55,016 | 55,072 | 55,101 | - | - |
Reference price 3 | 5.150 | 0.8678 | 1.180 | 1.520 | 1.520 | 1.520 |
Announcement Date | 31/03/22 | 11/04/23 | 16/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 1,142 | 255.9 | 206.7 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -631.4 | -772.8 | -449.3 | 607.4 | -334.5 | -474.1 |
Operating Margin | - | - | - | - | 53.17% | -130.71% | -229.4% |
Earnings before Tax (EBT) | - | -1,305 | -795 | - | - | - | - |
Net income 1 | -779.2 | -1,307 | -797.1 | -430.7 | -215.4 | -437.9 | -567.5 |
Net margin | - | - | - | - | -18.85% | -171.13% | -274.59% |
EPS 2 | -4.048 | -3.943 | -2.105 | -1.080 | 1.630 | -0.7340 | -0.9760 |
Free Cash Flow 1 | - | -570.8 | -679.7 | - | 629.7 | -318.5 | -412.6 |
FCF margin | - | - | - | - | 55.12% | -124.47% | -199.63% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 26/02/21 | 31/03/22 | 11/04/23 | 16/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | 152 | 990.3 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -181.4 | -181.4 | -363.1 | -205.5 | -205.5 | -401.8 | - | - | - | -101.3 | 708.6 |
Operating Margin | - | - | - | - | - | - | - | - | - | -66.67% | 71.56% |
Earnings before Tax (EBT) 1 | -181.3 | -181.3 | - | -200.3 | -200.3 | -400.5 | - | - | - | - | - |
Net income 1 | -182.2 | -182.2 | -364.3 | -200.6 | -200.6 | -401.3 | -395.8 | -212 | - | -135.2 | -80.2 |
Net margin | - | - | - | - | - | - | - | - | - | -88.94% | -8.1% |
EPS 2 | -0.5000 | -0.5000 | -0.7729 | -0.5256 | -0.5256 | -1.054 | -1.045 | -0.5348 | - | -0.3410 | -0.2020 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 31/03/22 | 31/03/22 | 31/03/22 | 13/09/22 | 13/09/22 | 13/09/22 | 11/04/23 | 12/09/23 | 16/04/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 1,706 | 1,059 | 859 | 830 | 1,487 | 960 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -571 | -680 | - | 630 | -318 | -413 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 24.9 | - | 2.13 | 7.24 | 7.24 | 14.5 |
Capex / Sales | - | - | - | - | 0.63% | 2.83% | 7% |
Announcement Date | 26/02/21 | 31/03/22 | 11/04/23 | 16/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.81% | 8.38Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- CNTB Stock
- Financials Connect Biopharma Holdings Limited